Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

Key Points

• Clear radiological and serological responses were noted in the patient after olaparib treatment, suggesting effectiveness in specific genetic contexts.
• The patient had a BRCA2 alteration and near-threshold tumor mutational burden, highlighting the importance of genetic profiling in cancer treatment.
• Assessment of treatment involved monitoring radiological changes alongside serum markers to evaluate response levels.
• Findings signify the potential for personalized treatment strategies based on genetic mutations and tumor characteristics.

Abstract